Evidence map›Paper›PMID 39956849›Full record

Trial reportSignal transduction and targeted therapy2025

ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Xichun Hu, Qingyuan Zhang, Leiping Wang, Jian Zhang, Quchang Ouyang, Xiaojia Wang, Wei Li, Weimin Xie, Zhongsheng Tong, Shusen Wang and 20 more

Abstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Antibody-drug conjugates in gastric cancer: clinical advances and resistance mechanisms.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Xichun Hu *Fudan University Cancer Hospital, Shanghai, 200032, China. huxichun@shca.org.cn.ORCID 0000-0001-6148-9186
Qingyuan Zhang *Harbin Medical University Cancer Hospital, Harbin, 150081, China.
Leiping Wang *Fudan University Cancer Hospital, Shanghai, 200032, China.
Jian Zhang *Fudan University Cancer Hospital, Shanghai, 200032, China.
Quchang OuyangHunan Cancer Hospital, Changsha, 410013, China.
Xiaojia WangZhejiang Cancer Hospital, Hangzhou, 310022, China.
Wei LiThe First Hospital of Jilin University, Changchun, 130031, China.
Weimin XieGuangxi Medical University Affiliated Tumor Hospital, Nanning, 530012, China.
Zhongsheng TongTianjin Medical University Cancer Institute & Hospital, Tianjin, 300060, China.
Shusen WangSun Yat-sen University Cancer Center, Guangzhou, 510060, China.ORCID 0000-0003-0139-5780
Faliang XuChongqing University Cancer Hospital, Chongqing, China.
Tao SunCancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, 110122, China.
Wei LiuThe Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Zhendong ChenThe Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Jinsheng WuThe First Affiliated Hospital of Hainan Medical University, Haikou, China.
Ying WangSun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Haixia WangHainan General Hospital, Haikou, China.
Min YanThe Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Xinshuai WangThe First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China.
Jingfen WangLinyi Cancer Hospital, Linyi, China.
Feilin CaoTaizhou Hospital, Wenzhou Medical University, Taizhou, China.
Yingying DuThe First Affiliated Hospital of Anhui Medical University, Hefei, China.
Yongqiang ZhangBeijing Hospital, Beijing, China.
Lilin ChenFirst Affiliated Hospital of Xiamen University, Xiamen, China.
Ping LuThe First Affiliated Hospital of Xinxiang Medical College, Xinxiang, China.
Sanyuan SunXuzhou Central Hospital, Xuzhou, China.
Ruiwen ZhangSanmenxia Central Hospital, Sanmenxia, China.
Aimin ZangAffiliated Hospital of Hebei University, Baoding, China.
Xiuqing NieNovoCodex Biopharmaceuticals, Shaoxing, China.
Yuan LeiNovoCodex Biopharmaceuticals, Shaoxing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This phase III trial aimed to compare ARX788, a site-specific, construct-homogeneous antibody-drug conjugate, with lapatinib plus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC) who had progressed on one line of trastuzumab based regimen. Eligible patients were randomized (1:1) to receive ARX788 (1.5 mg/kg, IV, Q3W) or lapatinib plus capecitabine (LC: lapatinib 1250 mg QD; capecitabine 1000 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCapecitabineErb-b2 Receptor Tyrosine KinasesImmunoconjugatesAdultAgedAged, 80 and overFemaleHumansLapatinibMiddle AgedCapecitabineERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesLapatinib

Identifiers

PMID39956849
PMCPMC11830773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.